Where does ADMS stock trade?

Adamas Pharmaceuticals, Inc. (ADMS) is listed on NASDAQ.

What sector and industry is ADMS in?

Adamas Pharmaceuticals, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.

When did Adamas Pharmaceuticals, Inc. go public?

Adamas Pharmaceuticals, Inc. (ADMS) completed its IPO in 2014.

What are analysts saying about ADMS?

Adamas Pharmaceuticals, Inc. has had 5 recent analyst actions on file. The most recent action was from Northland Capital Markets: Market Perform with a $850.00 price target on 2021-11-17. Recent price targets range from $800.00 to $910.00.

What companies are similar to ADMS?

Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare ADMS side-by-side with any of them on Quantisnow.

How can I track ADMS on Quantisnow?

Quantisnow aggregates Adamas Pharmaceuticals, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADMS to receive live email and push alerts on every new disclosure.

ADMS

NASDAQ

Adamas Pharmaceuticals, Inc.

SectorHealth CareIndustryMajor PharmaceuticalsIPO2014

$8.21+0.05 (+0.61%)

Follow Website

News25/Ratings5

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Latest news

25 items

ADMS FAQ

7 questions

What does Adamas Pharmaceuticals, Inc. do?
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced...
Where does ADMS stock trade?
Adamas Pharmaceuticals, Inc. (ADMS) is listed on NASDAQ.
What sector and industry is ADMS in?
Adamas Pharmaceuticals, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.
When did Adamas Pharmaceuticals, Inc. go public?
Adamas Pharmaceuticals, Inc. (ADMS) completed its IPO in 2014.
What are analysts saying about ADMS?
Adamas Pharmaceuticals, Inc. has had 5 recent analyst actions on file. The most recent action was from Northland Capital Markets: Market Perform with a $850.00 price target on 2021-11-17. Recent price targets range from $800.00 to $910.00.
What companies are similar to ADMS?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare ADMS side-by-side with any of them on Quantisnow.
How can I track ADMS on Quantisnow?
Quantisnow aggregates Adamas Pharmaceuticals, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADMS to receive live email and push alerts on every new disclosure.